INCELL
Innovative Life Science Solutions™
Menu
  • Home
    • Contact
    • Close
  • Products
    • Cart
    • Checkout
    • My Account
    • Close
  • Reg Med
    • Registrations Licenses & Certifications
    • Cell & Tissue Products
      • Regenerative & Stem Cells
      • Tissue-Derived Products
      • Reagents & Testing
      • INCELL Established Cell Lines
    • Tissue Collections & Kit Products
    • Storage of Cell & Tissue Products
    • Services: Manufacturing , Testing and R&D
      • Accelerated Product Development Services
      • Regenerative & Stem Cell Products
    • Close
  • Micro
    • Microbiology & Vaccine Products
      • Microbiology Testing
        • Sterility: GMP and USP Compliant
        • Microbial Bioburden
        • Endotoxin/Pyrogen Testing
        • Mycoplasma Testing
        • Antimicrobial & Microbiological Testing
        • Antimicrobials: New Product Testing In Vivo
    • Vaccines and Microbiology Products
      • Innovative Platforms, Tools and Vaccines
      • Microbiology & Vaccines Collaborations
    • Clinical Studies
    • Close
  • Clinical
    • Clinical Trials
    • Personalized Medicine
    • Close
  • About
    • Corporate
      • History
      • Mission
      • Registration, Licenses & Certificates
      • Memberships, Boards and Committees
    • Organization & Management
      • Board Members
        • Executive Managers
      • Key Alliances
        • Collaborative Business Model
    • Business Units & Activities
      • Regenerative Medicine
      • Media, Solutions & Kits
      • Microbiology & Vaccine Products
      • 503B Compounding & Formulation
    • Close
  • News
    • Close

Innovative Platforms, Tools and Vaccines

INCELL has developed key Innovative Platforms for new products and GMP manufacturing, including combination products. These platforms are supported by quality and capabilities in molecular, cellular, animal and clinical systems. Innovative Platforms of note are:

  • manufacturing components that meet GMP and CMC requirementskey-to-the-future-2
  • proprietary cell substrates
  • in vitro cell bioassays
  • adjuvants, GMP media and solutions
  • cryostorage methods and protective reagents
  • formulation, encapsulation and nanotechnologies
  • non-needle vaccine formulations
  • novel delivery technologies
  • stability design, formulations and bioassays

Considerations for New Vaccines

Factors important for development of INCELL vaccines are:

  • Rapid Development
  • Proprietary Formulation
  • Safe, Effective & Stable
  • Innate, mucosal, systemic immunity stimulated
  • Clear Development Path
  • Reasonable Costs
  • Closed Systems
  • Unit Dose Packaging
  • Preferred Non-needle (e.g., nasal, oral) = safety & lower cost delivery

ConsiderationsNewVaccinesConsiderationsNewVaccines

Cell substrates include INCELL’s cell lines used to propagate virus and to investigate host cell-microbial interactions. NCM cell lines have been used extensively in host cell and microbial interactions studies, and related work in metabolism, cytokines, chemokines, environment, nutrition, gut inflammation, colon cancer and pathogenesis mechanisms. This is documented in the published literature.

  PDS 2018 NCM356D Cell Line INCELL.pdf (344.3 KiB, 1,193 hits)

  PDS 2018 NCM460D Cell Line INCELL.pdf (599.5 KiB, 3,522 hits)

IBHK-4 cells are the substrate for growing IMVA, INCELL’s derived strain of Modified Vaccinia Ankara (MVA) and recombinant derivatives. Important features of the IBHK-4 cell line:

  • INCELL Proprietary cell substrate
  • Developed and tested as substrate for I-MVA
  • Derivative of BHK-21 (Baby Hamster Kidney) cell line
  • Grow in suspension in INCELL’s proprietary ACE™ medium
  • Can be cryostored in EZ-CPZ™ media ready for rapid response “Just-in-Time” (JITM) manufacturing in the REDIVAX Platform.
  • Support high titer IMVA, or IMVA as vector with select microbe recombinant genes (e.g., viruses such as influenza, ZIKA, and Ebola; or bacterial or fungal pathogens), with peak replication in less than 72 hr.
  • Components have been developed to meet GMP and CMC standards. Media and processes are in FDA Master Files.

IMVA =Vaccinia Virus/Vector for Vaccines:

  • Culture, titer, purity, potency, safety, efficacy, etc.
  • Missing large genomic regions allows new gene insertions to make MVA “vector construct” (e.g., with genes from influenza virus and other microbes)
  • In-licensed BAC-VAC shuttle vector technology from NIH.
  • Platform for Non-Needle Delivery

Examples: The figures (see right) show examples of effective non-needle, protective oral and nasal poxvirus vaccines with 100% survival and reduced morbidity (less weight loss, illness and lethargy) in animal challenge models.

Components that Meet GMP and CMC Needs

Innovative-Vaccine-GMP-manufacturing

 

REDIVAX™ Platform to Accelerate

Quick Response Vaccine Manufacturing

Innovative-Vaccine-components-to-accelerate

INCELL’s Effective Non-Needle Vaccines

Oral Vaccine = 100% Survival
vs. IM Injection or Mock Control Groups

Oral-Vaccine-Chart

MVA Vaccine was formulated and delivered to Oral and Injected Vaccine Groups. The Oral Mock Controls received Oral Vehicle Only. All were challenged with live, virulent vaccinia virus. The Mock Control had a 50% survival rate with high morbidity in the survivors compared to 100% survival for oral or IM vaccines and minimal morbidity (data not shown).

 


Intranasal Vaccine = 100% Survival
With No Weight Loss or Morbidity

Oral-Vaccine-Graph

MVA intranasal vaccine formula was delivered (100 ul) into the IM and Oral Vaccine Groups. The Oral Mock Control Group was Oral Vehicle Only and had a 50% survival rate compared to 100% for oral or IM vaccines.

Follow Us

Recent Posts

  • INCELL and Charter Medical Announce Exclusive Global Distribution Agreement
  • Dr. Moyer Addresses Orthopedic Physicians at AAOM National Meeting
  • INCELL Global Expansion
  • 2016 World Stem Cell Summit: INCELL-BIOTURNKEY Joint Venture
  • INCELL Sponsors WSCS in December 2016

Contact INCELL Corporation LLC

12734 Cimarron Path (Directions)
San Antonio, Texas 78249
Tel: 210-877-0100|Toll-free: 800.364.1765
Fax: 210-877-0200

Terms & Conditions | Privacy | Contact

Copyright © 2016. All Rights Reserved.

Designed by WebAuthorings.